Skip to main content
. 2019 Aug 7;2(8):e198686. doi: 10.1001/jamanetworkopen.2019.8686

Table 3. Association Between the Hyperinflammation and Immunosuppression and Normal Phenotypes and Long-term Outcomes.

Variables No. of Events/No. at Risk (%) Adjusted OR, HR, or SHR (95% CI)a P Value
Hyperinflammation and Immunosuppression Phenotype Normal Phenotype
All-cause 1-y mortality 77/326 (23.4) 6/141 (4.3) 8.26 (3.45-21.69) <.001
All-cause readmission or death, d
0-180 144/326 (44.2) 48/141 (34.0) 1.53 (1.10-2.13) .01
181-365 30/182 (16.5) 15/93 (16.1) 1.18 (0.64-2.20) .59
Readmission or death due to infection, d
0-180 79/326 (24.2) 27/141 (19.1) 1.35 (0.87-2.10) .18
181-365 22/217 (10.1) 5/114 (4.5) 2.00 (0.75-5.36) .17
Readmission or death due to cardiovascular disease, d
0-180 22/326 (6.7) 2/141 (1.4) 5.07 (1.18-21.84) .02
180-365 6/258 (2.3) 7/139 (5.0) 0.42 (0.14-1.28) .13
Readmission or death due to cancer, d
0-180 25/326 (7.7) 2/141 (1.4) 5.15 (1.25-21.18) .02
180-365 7/269 (2.6) 5/139 (3.6) 0.67 (0.20-2.27) .53

Abbreviations: HR, hazard ratio; OR, odds ratio; SHR, subdistribution hazard ratio.

a

The ORs were estimated using logistic regression model for all-cause 1-year mortality. The HRs were estimated using a Cox proportional hazards regression model for all-cause 1-year readmission or death. The SHRs were estimated using the Fine-Gray model for cause-specific analyses of death or readmission. Covariates included age, sex, race/ethnicity, Charlson Comorbidity Index score, APACHE II score, infection site, mechanical ventilatory support, vasopressor use, and dialysis.